Bayesian cancer clinical trial designs with subgroup-specific decisions-Reference-Cited by-同舟云学术

Bayesian cancer clinical trial designs with subgroup-specific decisions

Published:2020-03 Issue: Volume:90 Page:105860
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Thall Peter F.

Funder

NIH/NCI

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference21 articles.

1. Subgroup-specific dose finding in phase i clinical trials based on time to toxicity allowing adaptive subgroup combination;Chapple;Pharm. Stat.,2018

2. Analysis of ultivariate probit models;Dindo;Ann. Surg.,2004

3. New clinical trial designs in the era of precision medicine;Garralda;Mol. Oncol.,2019

4. Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity;Lee;J. Am. Stat. Assoc.,2015

5. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times;Lee;J. R. Stat. Soc. Ser. C: Appl. Stat.,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian Multivariate Logistic Regression for Superiority and Inferiority Decision-Making under Observable Treatment Heterogeneity;Multivariate Behavioral Research;2024-05-11

2. Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies;Clinical Trials;2024-01-11

3. Bayesian multilevel multivariate logistic regression for superiority decision-making under observable treatment heterogeneity;BMC Medical Research Methodology;2023-10-05

4. Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes;Clinical Cancer Research;2023-09-19

5. A Causal Framework for Making Individualized Treatment Decisions in Oncology;Cancers;2022-08-14